Skip to main content
Top
Published in: Gastric Cancer 1/2020

01-01-2020 | Adenocarcinoma of the Esophagogastric Junction | Review Article

Esophagogastric junction adenocarcinomas: individualization of resection with special considerations for Siewert type II, and Nishi types EG, E=G and GE cancers

Authors: Arnulf H. Hölscher, Simon Law

Published in: Gastric Cancer | Issue 1/2020

Login to get access

Abstract

For Siewert type II adenocarcinoma of the esophagogastric junction (AEG II), or similar tumors classified as Nishi EG, E=G, GE, the type of surgical resection and reconstruction should be individualized. Criteria for decision making mainly focus on the oral extent of esophageal infiltration, the cT and cN category and the functional status of the patient. For cT1/cT2 adenocarcinomas, which are non-poorly cohesive, intestinal type of Lauren Grading 1 or 2 without clinical signs of lymph node metastasis at the distal stomach, a limited transhiatal proximal gastrectomy with double tract reconstruction is recommended. For advanced adenocarcinomas, subtotal esophageal and proximal gastric resection with gastric pull-up or distal esophageal resection with total gastrectomy and esophagojejunostomy are competing procedures. Criteria for choosing the appropriate type of surgery are discussed.
Literature
1.
go back to reference Siewert JR, Hölscher AH, Becker K, Gossner W. Cardia cancer: attempt at a therapeutically relevant classification. Chirurg. 1987;58(1):25–32.PubMed Siewert JR, Hölscher AH, Becker K, Gossner W. Cardia cancer: attempt at a therapeutically relevant classification. Chirurg. 1987;58(1):25–32.PubMed
2.
go back to reference Hölscher AH, Schüler M, Siewert JR. Surgical treatment of adenocarcinomas of the gastroesophageal junction. Dis Esophagus. 1988;1:35–49.CrossRef Hölscher AH, Schüler M, Siewert JR. Surgical treatment of adenocarcinomas of the gastroesophageal junction. Dis Esophagus. 1988;1:35–49.CrossRef
3.
go back to reference Nishi MKT, Akune T, et al. Cardia cancer-proposal of cancer in the esophagogastric junction (in Japanese). Geka Shinryo (Surg Diagn Treat). 1973;15:1328–38. Nishi MKT, Akune T, et al. Cardia cancer-proposal of cancer in the esophagogastric junction (in Japanese). Geka Shinryo (Surg Diagn Treat). 1973;15:1328–38.
14.
go back to reference Hölscher AHBF, Hemmerich M, St Minot, Schmidt H. Double tract reconstruction following limited esophagogastric resection of AEG Types II and II adenocarcinomas. Zentralbl Chir. 2019;144:1–6.CrossRef Hölscher AHBF, Hemmerich M, St Minot, Schmidt H. Double tract reconstruction following limited esophagogastric resection of AEG Types II and II adenocarcinomas. Zentralbl Chir. 2019;144:1–6.CrossRef
15.
go back to reference Aikou TNS, Shimazu H, et al. Antrum preserving double tract method for reconstruction following proximal gastrectomy. Jpn J Surg. 1988;18:114–5.CrossRef Aikou TNS, Shimazu H, et al. Antrum preserving double tract method for reconstruction following proximal gastrectomy. Jpn J Surg. 1988;18:114–5.CrossRef
21.
go back to reference Hosoda K, Yamashita K, Moriya H, Mieno H, Ema A, Washio M, et al. Laparoscopically assisted proximal gastrectomy with esophagogastrostomy using a novel “Open-Door” technique: LAPG with Novel Reconstruction. J Gastrointest Surg. 2017;21(7):1174–80. https://doi.org/10.1007/s11605-016-3341-6(PubMed PMID: 28025772. Epub 2016/12/28).CrossRefPubMed Hosoda K, Yamashita K, Moriya H, Mieno H, Ema A, Washio M, et al. Laparoscopically assisted proximal gastrectomy with esophagogastrostomy using a novel “Open-Door” technique: LAPG with Novel Reconstruction. J Gastrointest Surg. 2017;21(7):1174–80. https://​doi.​org/​10.​1007/​s11605-016-3341-6(PubMed PMID: 28025772. Epub 2016/12/28).CrossRefPubMed
24.
go back to reference Lerut T, Nafteux P, Moons J, Coosemans W, Decker G, De Leyn P, et al. Three-field lymphadenectomy for carcinoma of the esophagus and gastroesophageal junction in 174 R0 resections: impact on staging, disease-free survival, and outcome: a plea for adaptation of TNM classification in upper-half esophageal carcinoma. Ann Surg. 2004;240(6):962–72.CrossRef Lerut T, Nafteux P, Moons J, Coosemans W, Decker G, De Leyn P, et al. Three-field lymphadenectomy for carcinoma of the esophagus and gastroesophageal junction in 174 R0 resections: impact on staging, disease-free survival, and outcome: a plea for adaptation of TNM classification in upper-half esophageal carcinoma. Ann Surg. 2004;240(6):962–72.CrossRef
25.
go back to reference Altorki N, Kent M, Ferrara C, Port J. Three-field lymph node dissection for squamous cell and adenocarcinoma of the esophagus. Ann Surg. 2002;236(2):177–83.CrossRef Altorki N, Kent M, Ferrara C, Port J. Three-field lymph node dissection for squamous cell and adenocarcinoma of the esophagus. Ann Surg. 2002;236(2):177–83.CrossRef
26.
go back to reference Omloo JM, Lagarde SM, Hulscher JB, Reitsma JB, Fockens P, van Dekken H, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann Surg. 2007;246(6):992–1000. https://doi.org/10.1097/sla.0b013e31815c4037(Discussion-1. PubMed PMID: 18043101. Epub 2007/11/29).CrossRefPubMed Omloo JM, Lagarde SM, Hulscher JB, Reitsma JB, Fockens P, van Dekken H, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann Surg. 2007;246(6):992–1000. https://​doi.​org/​10.​1097/​sla.​0b013e31815c4037​(Discussion-1. PubMed PMID: 18043101. Epub 2007/11/29).CrossRefPubMed
27.
go back to reference Hulscher JB, van Sandick JW, de Boer AG, Wijnhoven BP, Tijssen JG, Fockens P, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med. 2002;347(21):1662–9.CrossRef Hulscher JB, van Sandick JW, de Boer AG, Wijnhoven BP, Tijssen JG, Fockens P, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med. 2002;347(21):1662–9.CrossRef
28.
go back to reference Sasako M, Sano T, Yamamoto S, Sairenji M, Arai K, Kinoshita T, et al. Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. Lancet Oncol. 2006;7(8):644–51.CrossRef Sasako M, Sano T, Yamamoto S, Sairenji M, Arai K, Kinoshita T, et al. Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. Lancet Oncol. 2006;7(8):644–51.CrossRef
29.
go back to reference Kurokawa Y, Sasako M, Sano T, Yoshikawa T, Iwasaki Y, Nashimoto A, et al. Ten-year follow-up results of a randomized clinical trial comparing left thoracoabdominal and abdominal transhiatal approaches to total gastrectomy for adenocarcinoma of the oesophagogastric junction or gastric cardia. Br J Surg. 2015;102(4):341–8. https://doi.org/10.1002/bjs.9764(PubMed PMID: 25605628; PubMed Central PMCID: PMCPMC5024022. Epub 2015/01/22).CrossRefPubMedPubMedCentral Kurokawa Y, Sasako M, Sano T, Yoshikawa T, Iwasaki Y, Nashimoto A, et al. Ten-year follow-up results of a randomized clinical trial comparing left thoracoabdominal and abdominal transhiatal approaches to total gastrectomy for adenocarcinoma of the oesophagogastric junction or gastric cardia. Br J Surg. 2015;102(4):341–8. https://​doi.​org/​10.​1002/​bjs.​9764(PubMed PMID: 25605628; PubMed Central PMCID: PMCPMC5024022. Epub 2015/01/22).CrossRefPubMedPubMedCentral
Metadata
Title
Esophagogastric junction adenocarcinomas: individualization of resection with special considerations for Siewert type II, and Nishi types EG, E=G and GE cancers
Authors
Arnulf H. Hölscher
Simon Law
Publication date
01-01-2020

Other articles of this Issue 1/2020

Gastric Cancer 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine